He Yu-B (02256): The IND application for the orally administered small molecule KRAS G12D inhibitor ABSK141 has been approved by the FDA.

Zhtng Cijng APP news, Hy-B (02256) announced that its subsidiary, Shanghai Hy BioPharma Technology Co., Ltd., has announced that a new drug clinical trial application (IND) for ABSK141, an oral, highly active, highly selective small molecule KRAS G12D inhibitor for the treatment of advanced solid tumor patients carrying the KRAS G12D mutation, has been approved by the US Food and Drug Administration (FDA).